MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:AVAI)

0.1250 UNCHANGED
Streaming Delayed Price Updated: 2:46 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1250
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1250
Today's Range 0.1250 - 0.1250
52wk Range 0.1104 - 0.8000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell expertise through a research collaboration with Avaí Bio and Austrianova’s JV... 
From Avaí Bio, Inc.
Via GlobeNewswire
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-69.5%
-69.5%
1 Month
-16.5%
-16.5%
3 Month
-58.9%
-58.9%
6 Month
-70.9%
-70.9%
1 Year
-73.9%
-73.9%

More News

Read More
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Via FinancialNewsMedia
News headline image
Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security
From World Street Intelligence
Via GlobeNewswire
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From Equity Insider
Via GlobeNewswire
News headline image
Biotech Brief: Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
Via FinancialNewsMedia
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
From USA News Group
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Via FinancialNewsMedia
News headline image
5 Stocks Sitting on the Right Side of the Biggest Repricing in a Generation
From USA News Group
Via GlobeNewswire
News headline image
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
From Equity Insider
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
From Equity Insider
Via GlobeNewswire
News headline image
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
From USA News Group
Via GlobeNewswire
News headline image
THE FOUNDATION TRADE: 5 Assets Anchoring the Next Industrial Cycle
From USA News Group
Via GlobeNewswire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
From USA News Group
Via GlobeNewswire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
From USA News Group
Via GlobeNewswire
News headline image
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
From Avant Technologies Inc.
Via Business Wire
News headline image
THE CRITICAL LIST: 5 Stocks Anchoring the New Economy
From USA News Group
Via GlobeNewswire
News headline image
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
From USA News Group
Via GlobeNewswire
News headline image
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care
From USA News Group
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Via FinancialNewsMedia
News headline image
Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
From Avant Technologies, Inc.
Via Business Wire
News headline image
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
From Avant Technologies Inc.
Via Business Wire
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
Via FinancialNewsMedia
Topics Intellectual Property

Frequently Asked Questions

Is AVAI publicly traded?
Yes, AVAI is publicly traded.
What exchange does AVAI trade on?
AVAI trades on the OTC Traded
What is the ticker symbol for AVAI?
The ticker symbol for AVAI is AVAI on the OTC Traded
What is the current price of AVAI?
The current price of AVAI is 0.1250
When was AVAI last traded?
The last trade of AVAI was at 08/14/26 02:46 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story